Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Tarsus PharmaceuticalsTARS | Open-market sale10b5-1 plan | 06/17 | 06/22 | 10,000 sh2 trades | $61.55avg. | $615,488.26 | −1.2% | |
Jeffrey S. FarrowSEE REMARKS | Tarsus PharmaceuticalsTARS | Open-market sale | 06/16 | 06/17 | 14,396 sh | $60.95 | $877,436.2 | −20.2% |
Tarsus PharmaceuticalsTARS | Open-market sale10b5-1 plan | 06/15 | 06/17 | 12,500 sh2 trades | $62.12avg. | $776,495.16 | −10.5% | |
Katherine GoodrichDirector | Tarsus PharmaceuticalsTARS | Open-market sale10b5-1 plan | 06/15 | 06/17 | 2,954 sh | $62.08 | $183,384.32 | −57.0% |
Tarsus PharmaceuticalsTARS | Open-market sale10b5-1 plan | 03/20 | 03/24 | 2,989 sh | $66.75 | $199,515.75 | −3.5% | |
Tarsus PharmaceuticalsTARS | Open-market sale | 03/17–03/19 | 03/19 | 6,430 sh3 trades | $68.36avg. | $439,566.05 | −12.9% | |
Tarsus PharmaceuticalsTARS | Open-market sale | 03/17–03/19 | 03/19 | 13,056 sh3 trades | $68.36avg. | $892,528.42 | −17.5% | |
Tarsus PharmaceuticalsTARS | Open-market sale | 03/17–03/19 | 03/19 | 11,324 sh3 trades | $68.21avg. | $772,443.6 | −11.7% | |
Tarsus PharmaceuticalsTARS | Open-market sale | 03/17–03/19 | 03/19 | 34,603 sh3 trades | $68.34avg. | $2,364,903.81 | −50.9% | |
Tarsus PharmaceuticalsTARS | Open-market sale | 03/17–03/19 | 03/19 | 12,274 sh3 trades | $68.36avg. | $839,069.59 | −25.9% | |
Tarsus PharmaceuticalsTARS | Open-market sale | 03/17–03/19 | 03/19 | 12,440 sh3 trades | $68.36avg. | $850,417.03 | −16.3% | |
Tarsus PharmaceuticalsTARS | Open-market sale | 03/17–03/19 | 03/19 | 1,144 sh3 trades | $68.36avg. | $78,203.59 | −4.7% | |
Tarsus PharmaceuticalsTARS | Open-market sale10b5-1 plan | 03/16 | 03/18 | 12,500 sh3 trades | $68.79avg. | $859,818.7 | −9.7% | |
Tarsus PharmaceuticalsTARS | Open-market sale10b5-1 plan | 03/04 | 03/05 | 8,366 sh | $76.67 | $641,421.22 | −10.6% | |
Tarsus PharmaceuticalsTARS | Open-market sale10b5-1 plan | 01/02 | 01/06 | 15,565 sh4 trades | $80.67avg. | $1,255,683.96 | −40.0% | |
Tarsus PharmaceuticalsTARS | Open-market sale10b5-1 plan | 25/12/24 | 25/12/30 | 6,000 sh2 trades | $82.51avg. | $495,089.41 | −0.7% | |
Dianne C. WhitfieldChief Human Resources Officer | Tarsus PharmaceuticalsTARS | Open-market sale10b5-1 plan | 25/12/16 | 25/12/18 | 7,397 sh | $80.10 | $592,499.7 | −16.0% |
Elizabeth Yeu LinChief Medical Officer | Tarsus PharmaceuticalsTARS | Open-market sale | 25/12/16 | 25/12/17 | 2,078 sh | $79.50 | $165,201 | −8.7% |
Tarsus PharmaceuticalsTARS | Open-market sale10b5-1 plan | 25/12/15 | 25/12/17 | 22,946 sh5 trades | $81.26avg. | $1,864,677.82 | No record | |
Bobak R. AzamianPresident/CEO and Board Chair | Tarsus PharmaceuticalsTARS | Open-market sale10b5-1 plan | 25/09/24 | 25/09/26 | 6,000 sh | $55.37 | $332,220 | −0.7% |